CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

Abstract

We determined whether there

CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration

“…Genetic factors are known to play a major role in the pathogenesis of AMD and have been suggested to influence the response to different modalities of AMD therapy, including oral antioxidants, PDT, and anti-VEGF agents [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] . Other authors have studied the effect of the CFH rs1061170 (Y402H) on the response to PDT, with controversial results [10][11][12][13][14] .…”

“…Recent works have demonstrated the association between CFH rs1061170 (Y402H) SNP and the response to intravitreal injections of the anti-VEGF agents bevacizumab and ranibizumab [15][16][17][18][19][20][21][22][23][24] . Brantley et al evaluated patients that underwent intravitreal injections of bevacizumab at six-week intervals until there was no longer evidence of active neovascularization.…”

“…Other have evaluated the relationship between CFH genotypes and photodynamic therapy (PDT), with controversial results [12][13][14][15][16] . The association between gene polymorphisms and response to anti-vascular-endothelial growth-factor (VEGF) therapy for neovascular AMD has also been studied [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] . Intravitreal injections of anti-VEGF agents were the first treatment that consistently improved visual acuity (VA) in a large number of patients, representing a remarkable advance in the treatment of neovascular AMD.…”

“…However, there is a broad range of response rates to anti-VEGF therapy, and genetic variants may be partially responsible 6 . Several reports evaluated CFH genotype association with the response to the anti-VEGF agents bevacizumab and ranibizumab, some of them suggesting a potential pharmacogenetic relationship [17][18][19][20][21][22][23][24][25][26] . The purpose of this study was to investigate the association between CFH Y402H (rs1061170) SNP with response to ranibizumab therapy in neovascular AMD for the first time in a Brazilian population.…”

Clinical study of the correlation between complement factor H polymorphism and age-related macular degeneration

“…As our knowledge of genetics and inflammatory immunity has progressed, many genes associated with AMD are gradually being discovered, such as CFH, complement component 2, complement factor B, apolipoprotein E, hemicentin 1, and low-density lipoprotein receptor-related protein 6 (Dikmetas et al, 2013). The influence of CFH in this regard has been widely recognized in the literature, with the CFH polymorphism being identified as a key pathogenic factor in AMD, and used successfully in genetic studies to generate models of this disease (Imai et al, 2010;Abbas and Azzazy, 2013). Variation in the CFH gene mainly manifests as the polymorphism Y402H (T1277C), in which a T-to-C substitution at position 1277 in exon 9 leads to a change at residue 402 in the translated sequence, from tyrosine to histidine (Y402H).…”